

Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 in Primary Infection and Long-Term–Nonprogressive Infection

Alice K. Pilgrim, Giuseppe Pantaleo, Oren J. Cohen,
Lisa M. Fink, Ji Ying Zhou, Jin Tao Zhou,
Dani P. Bolognesi, Anthony S. Fauci,
and David C. Montefiori

Department of Surgery, Duke University Medical Center, Durham, North Carolina; Laboratory of AIDS Pathogenesis, Hôpital de Beaumont, Lausanne, Switzerland; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

The role of neutralizing antibodies in human immunodeficiency virus type 1 (HIV-1) infection is poorly understood and was assessed by evaluating responses at different stages of infection. Undiluted sera from long-term nonprogressors (LTNP) had broad neutralizing antibodies against heterologous primary isolates and were more likely to neutralize the contemporaneous autologous isolate than were sera from short-term nonprogressors and progressors. In primary infection, envelope-specific IgG was detected before the initial decline in plasma viremia, but neutralizing antibodies developed more slowly. Here, neutralizing antibodies against strains SF-2 and MN were sometimes the first to be detected, but titers were low for at least 17 weeks from onset of symptoms. Neutralizing antibodies against the early autologous isolate were detected for 4 patients by 5–40 weeks but were undetectable in 2 additional patients for 27–45 weeks. The results indicate that neutralizing antibody responses are slow to develop during primary infection and are uniquely broad in LTNP.

Infection with human immunodeficiency virus type 1 (HIV-1) is accompanied by cellular and humoral immune responses of various magnitudes and specificities that are thought to down-regulate plasma viremia during primary infection [1, 2] and to establish a period of clinical latency that follows [3]. Despite the benefit provided by these responses early in infection, nearly all HIV-1–infected persons progress to AIDS. Specific responses that are at least partially beneficial during the course of infection are poorly understood. Detection of HIV-1–specific cytotoxic T lymphocytes (CTL) correlates well with the initial down-regulation of plasma viremia during primary infection [4–7] and could be a dominant antiviral immune response. Another correlate during primary infection is the production of HIV-1–specific IgM [8] and possibly IgG [2, 9], but it is not clear whether these early antibodies are effective against the virus. For example, neutralizing antibody responses against the early autologous virus have been shown to be delayed relative to when plasma viremia is first down-regulated [5–7, 10]. Similar delays in neutralizing antibody production have been reported for simian immunodeficiency virus (SIV) infection in macaques [11, 12]. This slow development of neutralizing antibodies during primary infection might be one of the reasons the virus is able to establish persistent infection.

Although most infected persons progress to AIDS within a median time of 10 years from initial seroconversion, ~5%–10% tolerate infection without immune suppression or other clinical manifestations for longer periods of time [13–15]. This latter group of infected persons is referred to as long-term nonprogressors (LTNP). LTNP generally have low virus loads in their plasma, peripheral blood mononuclear cells (PBMC), and lymph nodes and mount robust cellular and humoral immune responses [16–21]. Some cases of long-term nonprogression are associated with infection by attenuated virus [22] or with a heterozygous defect in the CCR5 co-receptor [23]. Many other LTNP are thought to benefit from the overall quality of their immune responses.

Previous studies showed that neutralizing antibody responses in LTNP are greater in magnitude and breadth than they are in other HIV-1–infected persons. For example, the average titer of neutralizing antibodies against HIV-1_{IIB} and HIV-1_{MN} was significantly higher in sera from LTNP than from persons who had been infected for <7 years and had no signs of immune suppression [17]. In addition, we [17] and others [18] determined that sera from LTNP neutralize heterologous primary isolates more effectively than do sera from progressors. Importantly, it was not clear from these studies whether the greater capacity of sera from LTNP to neutralize primary isolates was merely a reflection of diminished response in immunologically suppressed persons.

The present study aimed to determine whether the broad neutralizing antibody responses seen in LTNP are unique compared with responses in other HIV-1–infected persons, including short-term nonprogressors (STNP) who had been infected for 2–7 years. We took advantage of the fact that virus neutralization was more readily detected with undiluted serum samples. By use of this approach, neutralizing antibodies in sera

Received 10 December 1996; revised 28 April 1997.

Informed consent, as approved by local institutional review boards and biosafety committees, was obtained from all patients and controls. The study followed human experimentation guidelines of the US Department of Health and Human Services.

Financial support: NIH (AI-45218, AI-28662).

Reprints or correspondence: Dr. David C. Montefiori, Dept. of Surgery, Box 2926, Duke University Medical Center, Durham, NC 27710.

The Journal of Infectious Diseases 1997;176:924–32
© 1997 by The University of Chicago. All rights reserved.
0022-1899/97/7604-0011\$02.00

from LTNP, progressors, recent seroconverters, and STNP were evaluated with autologous and heterologous primary isolates. We also determined whether low-level neutralizing antibodies might be present during primary infection that had previously gone undetected. Sequential serum samples obtained during and immediately following primary infection were assessed for neutralizing antibodies against the early autologous virus and T cell line-adapted (TCLA) variants of HIV-1, including IIIB, MN, and SF-2.

Methods

Study participants. HIV-1-infected LTNP and progressors were described previously [16, 17]. LTNP had well-documented infection for ≥ 10 years, were asymptomatic, and had >600 CD4 T lymphocytes/mm³ in their peripheral blood; these levels were stable over time. With the exception of 1 LTNP (no. 17), no LTNP received antiretroviral therapy. All progressors had signs of immunosuppression as evidenced by low CD4 T lymphocyte counts (range, 10–371/mm³). A group of STNP, defined as having documented infection for 2–7 years but remaining healthy, with >600 CD4 T lymphocytes/mm³, were recruited from the Durham, North Carolina, area. Information about antiretroviral therapy for progressors and STNP was unavailable.

Six persons with primary HIV-1 infection were referred for study by their private physicians. Each of them had developed transient mild clinical symptoms, which brought them to the attention of their physicians. Four of them began antiretroviral therapy within a few days of entry into study. Exceptions were patient 45, who received no antiretroviral therapy during the course of study, and patient 46, who began antiretroviral therapy ~ 25 weeks from the onset of symptoms. Healthy, HIV-1-negative persons were recruited from local research laboratories.

Primary isolates. Viruses were isolated by coculture of PBMC from infected persons with phytohemagglutinin-stimulated PBMC (PHA-PBMC) from healthy, noninfected persons in the presence of interleukin-2 (IL-2) as described [17]. Primary isolates from acute seroconverters were obtained at the time of their first serum collection. Virus stocks were made cell-free by low-speed centrifugation and passage through 0.5- μ m cellulose acetate filters before being stored in aliquots at -70°C . Some stocks were later expanded a single time in PHA-PBMC. TCID₅₀ was determined by the method of Reed and Muench [24] after 14 days of incubation with PHA-PBMC. Viral antigen concentration was measured by p24 immunoassay (DuPont, Wilmington, DE). Syncytium-inducing (SI) and non-SI (NSI) phenotypes were determined in MT-2 cells and PHA-PBMC as described [17]. The TCID₅₀, p24 concentration, and phenotype of each virus stock are given in table 1. Additional information on isolates obtained from LTNP and progressors has been published [17]. Primary isolates were used as either first- or second-passage stocks produced in PHA-PBMC.

Serologic assays. Neutralizing antibodies against TCLA strains of HIV-1 were measured in MT-2 cells (strains IIIB and MN) or CEMx174 cells (strain SF-2) in 96-well plates by a reduction in virus-induced cell killing as described previously [25]. In brief, cell-free virus (1000 TCID₅₀) and serial dilutions of test sera were incubated in triplicate at 37°C for 30 min before the addition

Table 1. Characteristics of primary isolates from HIV-1-infected subjects.

| Group, isolate | Phenotype | TCID ₅₀ | p24 (ng/mL)* | TCID ₅₀ /ng of p24 |
|--------------------------|-----------|--------------------|--------------|-------------------------------|
| Progressors | | | | |
| P59423 | NSI | 5.6×10^4 | 35.0 | 1600 |
| W25798 | NSI | 1.7×10^4 | 21.0 | 809 |
| W79290 | NSI | 7.5×10^3 | 31.4 | 239 |
| V89872 | SI | 1.3×10^5 | 29.8 | 4362 |
| V67970 | SI | 9.4×10^5 | 32.9 | 28,571 |
| W179273 | SI | 3.3×10^5 | 12.0 | 27,500 |
| STNP | | | | |
| P46471 | NSI | 9.4×10^5 | 61.0 | 15,410 |
| T00953 | NSI | 1.3×10^5 | 57.9 | 2245 |
| V91008 | NSI | 1.6×10^6 | 109.0 | 14,679 |
| W97464 | NSI | 9.4×10^5 | 39.6 | 23,738 |
| LTNP | | | | |
| 18 | NSI | 1.9×10^5 | 53.5 | 3551 |
| 22 | NSI | 1.9×10^5 | 600.0 | 317 |
| 24 | NSI | 1.3×10^5 | 67.7 | 1920 |
| Primary infection | | | | |
| 15 | NSI | 4.7×10^6 | 124.8 | 37,660 |
| 23 | NSI | 1.9×10^5 | 44.8 | 4241 |
| 27 | NSI | 2.8×10^5 | 25.3 | 11,067 |
| 30 | NSI | 2.1×10^6 | 60.0 | 35,000 |
| 45 | NSI | 3.8×10^4 | 4.7 | 8085 |
| 46 | NSI | 2.1×10^6 | 41.0 | 51,220 |

NOTE. STNP, short-term nonprogressors; LTNP, long-term nonprogressors; SI, syncytium-inducing; NSI, non-syncytium-inducing.

* Concentration of p24 at time of harvest from initial cocultivation.

of cells (5×10^4 /well). Cultures were then incubated for the minimum length of time that allowed for extensive syncytium formation to occur, as observed microscopically (3–4 days). Cell viability was quantified by neutral red staining as described [25]. Percentage of protection was calculated by the difference in absorbance at 540 nm between test wells (cells, serum sample, and virus) and virus control wells (cells and virus) divided by the difference in absorbance between cell control wells (cells only) and virus control wells. Neutralization titers were defined as the reciprocal of the serum dilution required to protect at least 50% of cells from virus-induced killing. Assays were standardized by including positive and negative control sera that had been assayed multiple times and for which the average titer was well-characterized. Virus stocks for these assays were produced in H9 cells.

Antibody-mediated neutralization of primary isolates was measured in PHA-PBMC as described [17] by use of a p24 immunoassay to quantify virus production. For assays with undiluted serum, 20 μL of cell-free virus was incubated with 80 μL of serum for 1 h at 37°C , and 25 μL of this mixture was added to triplicate wells containing PHA-PBMC (4×10^5 cells in 175 μL added per well). For measurement of titer, 50 μL of virus was incubated in triplicate as above with an equal volume of serum samples that were undiluted and diluted 1:2, 1:4, 1:16, and 1:32 (dilutions were made in IL-2 growth medium). Next, 25 μL was transferred to corresponding wells of U-bottom plates containing PHA-PBMC. Cells were incubated with the virus-serum mixtures for 3 h at 37°C and then washed three times with 200 μL of growth medium to

remove the virus inoculum and antibodies. Washed cells were suspended in 250 μ L of IL-2 growth medium and incubated in 96-well flat-bottom plates for the duration. Culture supernatants (25 μ L) were collected on a daily basis and mixed with 225 μ L of 0.5% Triton X-100 for the quantification of p24. This volume was replaced with 25 μ L of fresh IL-2 growth medium at each collection.

Viral p24 produced in the absence of test sera (virus control) was determined for each daily sampling and was used to construct a viral replication curve. Neutralization was measured at a time when the concentration of p24 in virus control wells exceeded 5 ng/mL (limit of detection was 0.1 ng/mL) but had not reached peak production (4–6 days). Serum samples were considered positive for primary isolate neutralization if they caused >80% reduction in p24 relative to a negative control serum (D01). This cutoff corresponds to a minimum 1 log reduction in infectious virus yield. Standard deviations for a given serum sample were divided by the average p24 value of the virus control and then multiplied by 100 for percentage. An equal volume of undiluted virus stock was used for all assays. While the infectious dose contained within this volume was not the same for all isolates, each serum sample was tested against an equal dose on a per-virus basis. Sera were heat-inactivated at 56°C for 1 h before use.

Antibodies that bound to HIV-1 antigens were assessed by HIV-1_{IIB} Western immunoblot (Cambridge Biotech, Worcester, MA) and by HIV-1_{MN} gp160 ELISA. Baculovirus-derived HIV-1_{MN} gp160 was obtained from Quality Biologicals (Gaithersburg, MD). ELISAs were done as described previously [26] with alkaline phosphatase-conjugated goat anti-human IgG (whole molecule; Sigma, St. Louis) and *p*-nitrophenylphosphate disodium hexahydrate (Sigma; catalog no. N-9389) used for detection and color development, respectively. Titers are reported as the reciprocal of the highest serum dilution to produce an average absorbance reading of at least twice that of a negative control serum (D01).

Removal of IgG. IgG was removed from serum samples by absorption with protein G-sepharose (GammaBind Plus Sepharose; Pharmacia, Piscataway, NJ). Protein G-sepharose was obtained by the supplier as a suspension in PBS containing thimerosal as a preservative. The resin was washed five times with PBS and collected by low-speed centrifugation as premeasured aliquots after the last wash. Supernatants were removed and replaced with a volume of undiluted serum equal to the volume of packed resin. Suspensions were incubated at room temperature for 1 h with constant gentle mixing. Protein G-sepharose was then separated from the serum by low-speed centrifugation, and the serum was collected by pipette. Serum samples were subjected to two additional absorption steps to ensure the removal of all IgG. Complete removal of HIV-1-specific IgG was confirmed by Western immunoblot analysis.

Measurements of plasma viremia. HIV-1 RNA in plasma samples was quantified by the branched DNA method as described previously [27].

Chemokine assays. Quantification of the chemokines RANTES and MIP-1 β in serum samples was done with commercially available ELISA kits as described by the supplier (R&D Systems, Minneapolis). Levels of RANTES and MIP-1 β were quantified when sufficient sample volumes were available. Levels of MIP-1 α were not measured because of a limited volume of serum samples.

Statistical analyses. The significance of the frequency by which sera from paired groups of infected persons neutralized primary isolates in a panel of 6 isolates was evaluated by χ^2 analysis with 1 *df*. This analysis assumed that the ability of a particular serum sample to neutralize one primary isolate does not predict its ability to neutralize other primary isolates. Yates's correction factor was used to give a more conservative estimate of *P*. Neutralization sensitivity of NSI and SI viruses was also compared by χ^2 analysis, but here sera from all infected persons were grouped as one. The small number of NSI and SI isolates (3 each) did not permit a comparison of neutralization sensitivity between sera from different subgroups of persons.

Results

Autologous and heterologous neutralizing antibody responses at different stages of HIV-1 infection. Serum samples obtained at different stages of HIV-1 infection were assessed for neutralization breadth with a panel of 6 primary isolates. Sera from 6 recent seroconverters (sera obtained 13–53 weeks from onset of symptoms), 5 progressors, 6 STNP, 6 LTNP, and 5 healthy HIV-1-negative persons were used in this evaluation (table 2). Primary isolates were derived from the progressors listed in table 2. These same primary isolates and sera from progressors and LTNP were used in a previous study in which the primary isolates were rarely neutralized by 1:16-diluted serum samples [17]. Undiluted serum was used in the present study to improve the detection of neutralizing antibodies.

No neutralization of primary isolates was detected with sera from HIV-1-negative persons. In some cases, mild enhancement of infection was observed with these sera, but the enhancing effect was never more than a doubling of p24 production, which would not be considered true enhancement [12, 17]. Neutralization of each virus was detected sporadically with serum samples from HIV-1-infected persons. Positive neutralization was detected most often with sera from LTNP. Of the LTNP sera evaluated, 20 (56%) of 36 virus-serum combinations tested positive. Neutralization was detected less frequently with sera from STNP (25% of combinations testing positive), recent seroconverters (17% of combinations testing positive), and progressors (17% of combinations testing positive). The breadth of neutralization was significantly greater for sera from LTNP compared with sera from all other groups ($P = .0014$ compared with recent seroconverters, $P = .0028$ compared with progressors, and $P = .0163$ compared with STNP; 95% confidence level). The breadth of neutralization with sera from STNP was no greater than with sera from recent seroconverters or progressors ($P > .05$). There was also no significant difference in neutralization sensitivity between NSI and SI viruses when sera from all infected persons were grouped as one for the analysis ($P = .124$).

Undiluted sera from LTNP neutralized the autologous virus obtained at the time of serum collection in all 3 cases examined (table 3). These same sera had failed to neutralize the autologous virus at a 1:16 dilution previously [17]. Isolates from

Table 2. Neutralization of primary isolates by undiluted sera obtained at different stages of HIV-1 infection.

| Group, serum no. (weeks from symptom onset) | Neutralization of primary isolate | | | | | |
|---|-----------------------------------|----------------|----------------|----------------|---------------|----------------|
| | P59423 | W25798 | W79290 | V89872 | V67970 | W179273 |
| Recent seroconverters | | | | | | |
| 15 (53) | 96 ± 0 | 97 ± 1 | 96 ± 2 | 19 ± 30 | 66 ± 5 | 71 ± 10 |
| 23 (45) | 14 ± 34 | 28 ± 19 | 98 ± 1 | 4 ± 25 | 4 ± 17 | -3 ± 39 |
| 27 (27) | 39 ± 16 | 65 ± 5 | 91 ± 2 | 44 ± 19 | 27 ± 19 | 52 ± 12 |
| 30 (13) | 17 ± 63 | 37 ± 31 | 30 ± 14 | 9 ± 18 | -9 ± 39 | -6 ± 32 |
| 45 (25) | 56 ± 21 | 69 ± 3 | 91 ± 9 | 51 ± 19 | 30 ± 24 | 51 ± 22 |
| 46 (13) | 22 ± 23 | 61 ± 7 | 80 ± 7 | 23 ± 20 | -11 ± 34 | 35 ± 18 |
| Progressors | | | | | | |
| P59423 | 67 ± 18 | 97 ± 1 | -58 ± 41 | 9 ± 4 | 96 ± 1 | -29 ± 12 |
| W25798 | 90 ± 15 | 88 ± 11 | -15 ± 19 | -17 ± 38 | 28 ± 33 | -6 ± 21 |
| V89872 | 12 ± 22 | 85 ± 12 | 56 ± 16 | -51 ± 46 | 61 ± 21 | 34 ± 19 |
| V67970 | 0 ± 44 | 61 ± 78 | 70 ± 39 | 5 ± 30 | 33 ± 10 | -1 ± 43 |
| W179273 | 22 ± 27 | 43 ± 36 | -85 ± 72 | -81 ± 59 | 8 ± 9 | -16 ± 32 |
| STNP | | | | | | |
| T00953 | 92 ± 11 | 99 ± 1 | 87 ± 10 | 36 ± 11 | 99 ± 0 | 98 ± 1 |
| V91008 | 19 ± 39 | 17 ± 29 | 38 ± 18 | 91 ± 6 | 99 ± 0 | 86 ± 15 |
| W97464 | -19 ± 29 | 8 ± 33 | 26 ± 15 | 3 ± 8 | 67 ± 3 | -55 ± 61 |
| P46471 | 44 ± 16 | -6 ± 52 | 23 ± 9 | 26 ± 44 | 54 ± 29 | 79 ± 26 |
| T84136 | 48 ± 28 | 20 ± 55 | 35 ± 16 | 93 ± 4 | 2 ± 54 | 1 ± 5 |
| W55819 | 43 ± 3 | 20 ± 13 | 7 ± 19 | 42 ± 28 | 17 ± 46 | 26 ± 44 |
| LTNP | | | | | | |
| 1 | 100 | 100 | 100 | 85 ± 10 | 90 ± 8 | 100 |
| 2 | 82 ± 18 | 87 ± 11 | -3 ± 77 | 38 ± 24 | 98 ± 3 | 95 ± 6 |
| 3 | 96 ± 5 | 96 ± 4 | 47 ± 33 | 42 ± 21 | 100 | 97 ± 2 |
| 9 | 39 ± 11 | 51 ± 58 | -28 ± 127 | 31 ± 21 | 62 ± 19 | 74 ± 21 |
| 10 | 100 | 100 | -15 ± 126 | 53 ± 4 | 100 | 83 ± 24 |
| 17 | 70 ± 12 | 60 ± 17 | 81 ± 23 | 11 ± 19 | 88 ± 9 | 23 ± 14 |
| HIV-1-negative subjects | | | | | | |
| D01 | -21 ± 42 | 9 ± 35 | 23 ± 20 | -47 ± 70 | 24 ± 4 | 24 ± 20 |
| D02 | -44 ± 30 | 32 ± 14 | 35 ± 1 | -80 ± 28 | 2 ± 22 | -38 ± 31 |
| D03 | -48 ± 41 | 18 ± 14 | 15 ± 25 | -64 ± 35 | -11 ± 22 | 0 ± 9 |
| D04 | -40 ± 7 | 23 ± 9 | 9 ± 8 | -62 ± 13 | 29 ± 19 | -42 ± 37 |
| D05 | 7 ± 9 | 14 ± 8 | 35 ± 10 | -32 ± 19 | 23 ± 22 | -3 ± 11 |

NOTE. Virus neutralization was measured in phytohemagglutinin-stimulated peripheral blood mononuclear cells by using undiluted serum. Values are % reduction in p24 production relative to virus control (no test serum) in HIV-1-negative subjects and relative to p24 production in presence of serum D01 for all others. Results are given as average of triplicate wells ± SD. Boldface type indicates >80% reduction (positive for neutralization). STNP, short-term nonprogressors; LTNP, long-term nonprogressors.

progressors were neutralized by undiluted autologous serum in only 1 of 5 cases examined (table 2), whereas isolates from STNP were neutralized by undiluted autologous serum in 0 of 4 cases examined (table 3).

Virus neutralization by undiluted serum is antibody-mediated. We examined whether high concentrations of antiviral cytokines or chemokines in undiluted serum were at least partially responsible for neutralizing activity. Protein G-sepharose was used to remove the total IgG from 5 serum samples that had previously neutralized 1 or more primary isolates. Samples were negative for anti-HIV-1 antibodies by Western blot analysis after absorption (data not shown). Serum samples were reevaluated for virus neutralization before and after absorption. As can be seen in table 4, samples absorbed with protein G-

sepharose no longer had neutralizing activity. Loss of neutralizing activity could not be attributed to sample dilution during absorption, since the volume of processed samples never exceeded the original preabsorption volumes. These results strongly indicate that virus neutralization was mediated by IgG.

Antibody-independent neutralization was further assessed by quantifying the concentration of the anti-HIV-1 chemokines, RANTES and MIP-1β in serum samples (table 5). Many infected persons had moderately elevated levels of RANTES in their serum compared with levels in serum from healthy, noninfected persons (>14.8 ng/mL). Elevated levels were mostly seen in sera from progressors, and these particular serum samples had poor neutralizing activity against primary isolates. Only 1 infected subject had a level of MIP-1β that

Table 3. Neutralization of primary isolates from long-term and short-term nonprogressors (LTNP and STNP) by autologous serum.

| Subject | Status | Neutralization of autologous virus |
|---------|--------|------------------------------------|
| 18 | LTNP | 99 ± 0 |
| 22 | LTNP | 94 ± 3 |
| 24 | LTNP | 99 ± 0 |
| P46471 | STNP | 30 ± 18 |
| T00953 | STNP | 45 ± 18 |
| V91008 | STNP | 52 ± 13 |
| W97464 | STNP | 32 ± 9 |

NOTE. Undiluted serum from each subject was evaluated for neutralizing antibodies against autologous isolate obtained at time of serum collection. Values are % reduction in p24 production in phytohemagglutinin-stimulated peripheral blood mononuclear cells and are given as average of triplicate wells ± SD.

was highly elevated relative to all others. This subject (V89872) was a progressor whose serum rarely neutralized primary isolates. Sera with the most potent neutralizing activity (i.e., serum samples 3, 10, and T00953) had lower concentrations of these chemokines than did the remaining sera that had poor or no neutralizing activity. We conclude that virus neutralization using undiluted serum was unrelated to the concentration of anti-HIV-1 chemokines.

CD4 T cells, plasma virus loads, and serum antibody responses during primary infection. CD4 T cells, plasma virus, and serum antibodies were quantified for HIV-1-infected persons starting at 3–10 weeks from onset of symptoms and continuing for an additional 20–57 weeks thereafter (table 6). Four of 6 patients had

Table 5. Analysis of serum chemokine concentrations at different stages of HIV-1 infection.

| Group, serum | RANTES (ng/mL) | MIP-1β (pg/mL) |
|--------------|----------------|----------------|
| Progressors | | |
| W25798 | 77.8 | NT |
| V89872 | 55.5 | 153.8 |
| V67970 | 68.0 | 20.3 |
| STNP | | |
| T00953 | 19.8 | 8.5 |
| P46471 | 47.6 | 52.5 |
| T84136 | 10.6 | 25.0 |
| LTNP | | |
| 3 | 20.5 | NT |
| 10 | 18.3 | NT |
| 17 | 21.7 | 41.4 |
| 18 | 17.6 | 58.6 |
| Controls | | |
| D01 | 9.3 | 22.2 |
| D02 | 13.5 | 54.2 |
| D03 | 6.8 | 13.7 |
| D04 | 14.8 | 10.2 |

NOTE. LTNP, long-term nonprogressors; STNP, short-term nonprogressors; NT, not tested.

levels of plasma viremia of $>10^5$ RNA copies/mL at the earliest time point examined. These levels subsequently declined and remained persistently low in 3 of them (patients 15, 23, and 30), all of whom began antiretroviral therapy shortly after the first time point. The fourth patient with high levels of plasma virus on entry continued to have high virus loads for 20 weeks of follow-up (patient 45); this patient received no antiretroviral ther-

Table 4. Neutralization of primary isolates after removing IgG from serum samples.

| Serum, IgG | Neutralization of primary isolate | | | | | | |
|---------------|-----------------------------------|---------|---------|--------|--------|---------|---------|
| | P59423 | W25798 | W79290 | V89872 | V67970 | W179273 | 18 |
| 15 (53 weeks) | | | | | | | |
| + | 82 ± 4 | 95 ± 2 | 94 ± 4 | NT | NT | NT | NT |
| - | 26 ± 16 | 11 ± 16 | 59 ± 48 | NT | NT | NT | NT |
| T00953 | | | | | | | |
| + | NT | NT | NT | NT | 99 ± 1 | 97 ± 3 | NT |
| - | NT | NT | NT | NT | 0 ± 22 | 15 ± 52 | NT |
| V91008 | | | | | | | |
| + | NT | NT | NT | 89 ± 4 | 100 | NT | NT |
| - | NT | NT | NT | 0 ± 39 | 0 ± 15 | NT | NT |
| 10 | | | | | | | |
| + | NT | 100 | NT | NT | 100 | NT | NT |
| - | NT | 0 ± 37 | NT | NT | 0 ± 19 | NT | NT |
| 18 | | | | | | | |
| + | NT | NT | NT | NT | NT | NT | 87 ± 7 |
| - | NT | NT | NT | NT | NT | NT | 14 ± 45 |

NOTE. Undiluted sera were evaluated for neutralizing antibodies against indicated primary isolate. Values are % reduction in p24 production in phytohemagglutinin-stimulated peripheral blood mononuclear cells and are given as average of triplicate wells ± SD. NT, not tested. Samples were evaluated before (+) and after (-) IgG was removed by absorption with protein G-sepharose.

Table 6. CD4 T cells, plasma virus concentration, and antibody titers in primary HIV-1 infection.

| Patient, weeks from symptom onset* | CD4 T cells/mm ³ | Plasma virus [†] | ELISA titer [‡] | Neutralizing antibody titer [§] | | | |
|--|--------------------------------|------------------------------|-----------------------------|--|------|------|------|
| | | | | Autologous isolate | IIIB | MN | SF-2 |
| Patient 15 | | | | | | | |
| 4 | 704 | 744,000 | 150 | <2 | <10 | <10 | <10 |
| 20 | 638 | 13,000 | 4050 | 4 | <10 | 24 | 393 |
| 25 | 542 | 19,000 | 4050 | 8 | 26 | 55 | 490 |
| 29 | 502 | 11,000 | 12,150 | 32 | 82 | 125 | 830 |
| 35 | 655 | 12,000 | 36,450 | 32 | 67 | 156 | 713 |
| 53 | 644 | <10,000 | 36,450 | >64 | 72 | 149 | 1932 |
| Patient 23 | | | | | | | |
| 10 | 756 | 171,000 | 450 | <2 | <10 | 23 | 14 |
| 18 | 523 | 137,000 | 1350 | <2 | <10 | 78 | 136 |
| 25 | 484 | 19,000 | 4050 | <2 | <10 | 157 | 520 |
| 29 | 385 | 31,000 | 4050 | <2 | 12 | 200 | 665 |
| 42 | 363 | 41,000 | 4050 | <2 | <10 | 342 | 661 |
| 45 | 391 | 58,000 | 12,150 | <2 | <10 | 199 | 1039 |
| Patient 27 | | | | | | | |
| 4 | 441 | 40,000 | 150 | <2 | <10 | <10 | <10 |
| 5 | NT | NT | 450 | <2 | <10 | <10 | <10 |
| 6 | 313 | <10,000 | 450 | <2 | 22 | 29 | <10 |
| 11 | 395 | <10,000 | 1350 | <2 | <10 | 72 | 20 |
| 17 | 359 | <10,000 | 1350 | <2 | 14 | 24 | 840 |
| 27 | 357 | 15,000 | 4050 | <2 | 24 | 72 | 552 |
| Patient 30 | | | | | | | |
| 3 | 558 | 1,224,000 | 1350 | <2 | <10 | <10 | <10 |
| 7 | 679 | 37,000 | 1350 | <2 | 24 | 16 | <10 |
| 13 | 665 | <10,000 | 1350 | <2 | 32 | 23 | 226 |
| 18 | 655 | 12,000 | 1350 | <2 | 29 | 71 | 778 |
| 40 | 525 | <10,000 | 4050 | 2 | 48 | 144 | 2014 |
| Patient 45 | | | | | | | |
| 5 | 502 | 594,000 | 450 | 2 | <10 | <10 | <10 |
| 12 | 613 | 377,000 | 1350 | 2 | <10 | <10 | <10 |
| 20 | 651 | 297,000 | 1350 | 4 | 23 | 200 | 14 |
| 25 | 722 | 230,000 | 4050 | 16 | 43 | 137 | 20 |
| Patient 46 | | | | | | | |
| 5 | 848 | 43,000 | 4050 | <2 | 49 | 235 | 46 |
| 13 | 498 | 70,000 | 4050 | 2 | 120 | 236 | 143 |
| 30 | 436 | <10,000 | 1350 | 8 | 308 | 685 | 2335 |
| 51 | 400 | <500 | 450 | 32 | 227 | 544 | 762 |
| 62 | 488 | <500 | 1350 | 32 | 279 | 1317 | 2066 |

NOTE. NT, not tested.

* Virus was isolated from each patient at first time point indicated.

[†] Quantified by branched DNA assay. Values are copies of viral RNA/mL of plasma.

[‡] Envelope-specific IgG was quantified by ELISA using HIV-1_{MN} gp160 as antigen for detection.

[§] Neutralizing antibodies were measured in human peripheral blood mononuclear cells against early autologous isolate obtained ~1 month from onset of symptoms. Neutralizing antibodies to HIV-1_{IIIB} and HIV-1_{MN} were measured in MT-2 cell-killing assay, whereas neutralizing antibodies to HIV-1_{SF-2} were measured in CEMx174 cell-killing assay. Values are reciprocal of highest serum dilution to reduce production of p24 by >80% relative to negative control serum D01 (primary isolates) or to result in 50% reduction in virus-induced cell killing (strains IIIB, MN, and SF-2).

apy. Two remaining patients (27 and 46) had moderate levels of plasma virus at the earliest time point examined; these levels were undetectable by weeks 5 and 30 of follow-up, respectively, and remained low or undetectable thereafter. The last 2 patients began antiretroviral therapy shortly before plasma viremia declined to undetectable levels.

Envelope-specific IgG to HIV-1_{MN} gp160 was detected by ELISA at the earliest time point for all 6 patients (table 6). Seroconversion to the viral envelope glycoproteins at these early time points was confirmed by HIV-1_{IIIB} Western blot analysis (data not shown). Despite early seroconversion, development of neutralizing antibodies to the early autologous iso-

late was delayed in most patients. For example, autologous neutralizing antibodies in sera from patients 23, 27, and 30 were undetectable for 45, 27, and 18 weeks from onset of symptoms, respectively. Neutralizing antibodies in sera from patient 15 were undetectable at 4 weeks but were present at a titer of 1:4 by 20 weeks and rose to a titer >1:64 by 53 weeks. Patient 45 developed low-titer (1:2) autologous neutralizing antibodies by week 5, and the titer increased to 1:16 by week 25. This patient received no antiretroviral therapy and maintained high levels of plasma HIV-1 RNA of 594,000–230,000 copies/mL during this period of time. Patient 46 developed detectable neutralizing antibodies to his early autologous isolate by week 13 (titer of 1:2), and the titer steadily rose to 1:32 by week 51 and was maintained at week 62. This latter patient began antiretroviral therapy at about week 25, which was followed by a drop in plasma HIV-1 RNA to undetectable levels while titers of autologous neutralizing antibodies continued to increase. Neutralizing antibodies to the early autologous isolate were undetectable in sera from patients 23 and 27 throughout the entire period of follow-up (i.e., 45 and 27 weeks from onset of symptoms, respectively).

Neutralizing antibodies were detected within 5–20 weeks from onset of symptoms when TCLA strains of HIV-1 were used for detection (table 6). These neutralizing antibodies were most effective against strain SF-2, followed by MN and, to a much lesser degree, IIIB. Titers of neutralizing antibodies were relatively low before 17 weeks for SF-2 and for a considerably longer period of time for MN and IIIB. For example, average titers of neutralizing antibodies in sera from asymptomatic HIV-1-infected persons infected for 2–7 years are 1:345 and 1:680 for IIIB and MN, respectively [17], and 1:2259 for SF-2 (data not shown) in the same assay as that used above. On the basis of these average titers and the data presented in table 6, the development of high-titer neutralizing antibodies to IIIB and MN usually requires >25–53 weeks of infection.

Finally, 3 of 6 seroconverters showed signs of immune suppression within 1 year from the onset of symptoms, as evidenced by a drop in CD4 T cells below 500/mm³ (patients 23, 27, and 46). This immune suppression showed no obvious correlation with plasma virus loads or neutralizing antibody responses.

Discussion

Our results show that long-term nonprogressive HIV-1 infection is associated with broad neutralizing antibody responses against primary isolates. Similar results have been reported [17, 18], but those studies did not determine whether broad responses were unique to LTNP. Our results showed that neutralizing antibodies in sera from LTNP are reactive against a broader spectrum of primary isolates than are sera from progressors and non-immune-suppressed asymptomatic persons who had been infected for <7 years (STNP). In addition, sera from LTNP were more likely to neutralize the contemporane-

ous autologous isolate than were sera from STNP or progressors.

Broadly cross-reactive neutralizing antibodies in sera from LTNP might be explained by responses against highly conserved epitopes, such as those recognized by the human monoclonal antibodies 2G12, IgG1b12, and 2F5 (reviewed in [28]) or by multiple responses to isolate-specific epitopes that accumulated over time [29]. The sporadic neutralization of our primary isolates by many sera suggests that variable, isolate-specific epitopes dominate the neutralizing antibody response. It is reasonable to assume that the virus regularly mutates to escape contemporaneous neutralizing antibodies against these variable epitopes. Consistent with this, Delwart et al. [30] observed a high and constantly changing complexity of viral quaspecies in LTNP over time. This could create a wide range of neutralization epitopes for antigen presentation and eventually lead to broadly cross-reactive neutralizing antibodies after long-term nonprogressive infection.

Early neutralizing antibody responses would have to be long-lived to become cumulative over time as an explanation for the broad responses in LTNP. Our results showed that neutralizing antibodies against early isolates continue to rise in titer for at least 1 year (patients 15 and 46, table 6). Others have shown that isolate-specific neutralizing antibody responses may be maintained for at least 2–3 years [29, 31–33]. Whether these responses can last for even longer periods of time has not been addressed. Isolate-specific neutralizing antibody responses would be maintained if the autologous virus persisted either as a minor population of replicating virus or as immune complexes on follicular dendritic cells. Additional studies are needed to determine more precisely the longevity of isolate-specific neutralizing antibody responses in HIV-1-infected persons and whether neutralization-escape variants arise periodically in LTNP.

It should be noted that the titers of neutralizing antibodies against primary isolates were low. Specifically, neutralizing antibodies detected in undiluted sera from progressors and LTNP were much broader than those detected previously [17] when the same serum samples were evaluated at a 1:16 dilution against this panel of primary isolates. The earlier study also determined that autologous neutralizing antibodies against viruses from 3 of 3 LTNP tested were undetectable at a 1:16 serum dilution, whereas here they were detected for all 3 LTNP when undiluted serum was used. Although the titers of these neutralizing antibodies were low, they may still be significant in the host, where they are undiluted.

Our detection of virus neutralization with undiluted serum raised the possibility that antiviral cytokines, such as the interferons [25], or antiviral chemokines, such as RANTES, MIP-1 α , MIP-1 β [34], and SDF-1 [35, 36], were partially responsible. Clearly this was not the case for sera from HIV-1-negative persons, since no neutralization was detected. It remained possible that the levels of antiviral cytokines and chemokines in serum are elevated during HIV-1 infection. We examined this

possibility and found that RANTES and MIP-1 β were not elevated in serum samples with broad neutralization activity. Others have shown that serum chemokine levels are similar for LTNP and progressors and that these levels are below those reported to block HIV-1 infection *in vitro* [37]. Additional evidence that neutralization was antibody-mediated came from lack of neutralization when IgG was removed from serum samples. The virus neutralization detected with undiluted serum samples was therefore most likely antibody-mediated.

Our improved detection of primary isolate neutralization with undiluted serum led us to investigate how soon after primary infection autologous neutralizing antibodies could be detected. Most studies agree that neutralizing antibodies are slow to develop and do not correlate with the initial down-regulation of plasma viremia during primary infection [5–7, 10]. The initial down-regulation in plasma viremia in the patients followed here was probably due to a combination of their immune response and antiretroviral therapy. Our results agree that autologous neutralizing antibodies against the early isolate are slow to develop in many persons, even when measured with a 1:2 serum dilution. Possible exceptions were found with 3 patients who developed detectable autologous neutralizing antibodies within 5–20 weeks from onset of symptoms (patients 15, 45, and 46, table 6). These antibodies might have been present sooner, but appropriate samples were not available for analysis. Of particular interest was patient 45; this patient received no antiretroviral therapy and had high levels of plasma viremia (>230,000 viral RNA copies/mL) at all time points even though neutralizing antibodies against the early isolate were detected within 5 weeks from onset of symptoms. Neutralization-escape variants might have rapidly emerged in this person.

In addition to autologous primary isolates, several neutralization-sensitive TCLA strains of HIV-1 were used to assess neutralizing antibodies following seroconversion. Interestingly, neutralizing antibodies against strains MN and SF-2 were detected well before the detection of neutralizing antibodies against the autologous virus in 3 of 6 infected persons. A similar phenomenon has been described for neutralization-resistant variants of SIV in macaques [12, 38]. One possible explanation is that primary isolates contain neutralization epitopes that are shared with TCLA virus and are immunogenic but either are poorly exposed on primary isolate envelope glycoproteins or are not needed for primary isolate infectivity. In the case of poorly exposed epitopes, neutralizing antibodies that are specific for TCLA viruses could be induced when monomeric gp120 and gp160 are released into circulation by infected cells or when infected cells are killed by cytotoxic T lymphocytes. One region that appears to contain neutralization epitopes that are hidden in native, oligomeric gp120 is the V3 loop [39], which also is an important region for co-receptor interactions [40, 41].

We conclude that neutralizing antibodies are slow to develop during primary infection and are uniquely broad in LTNP. The slow development of neutralizing antibodies during primary

infection could allow the virus to establish persistent infection. In this regard, any means of accelerating the neutralizing antibody response, such as by vaccination, might provide a clinical benefit that is not realized by the natural response to infection. Neutralization epitopes recognized by sera from LTNP would be interesting to pursue for HIV-1 vaccine development. We also wish to emphasize that envelope-specific IgG was detected very early during primary infection. Similar results have been reported previously [2], and although these antibodies are non-neutralizing, they might still provide a benefit by participating in antibody-dependent cellular cytotoxicity [7, 42] or in complement-mediated clearance [43, 44]. Finally, it may be possible that continuous and high production of circulating virus [45] will sometimes remove a significant portion of neutralizing antibodies and that these antibodies are not replenished at a pace to keep up with their removal. Our studies do not eliminate this as a possible explanation for cases in which neutralizing antibody titers were low or undetectable.

Acknowledgments

We thank the HIV-1–infected persons who participated in this study. We also thank all of the investigators associated with the Multicenter AIDS Cohort Study, particularly Roger Detels, John Phair, Charles Rinaldo, and Alfred Saah; the San Francisco City Clinic Cohort Study, particularly Susan Buchbinder; the NIAID lymph node study, particularly Mauro Vaccarezza; and their staffs, who cooperated in recruiting study subjects.

References

- Daar ES, Moudgil T, Meyers RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. *N Engl J Med* 1991;324:961–4.
- Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. *N Engl J Med* 1991;324:954–60.
- Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. *Ann Intern Med* 1995;122:573–9.
- Pantaleo G, Demarest JF, Soudeyns H, et al. Major expansion of CD8⁺ T cells with a predominant V β usage during the primary immune response to HIV. *Nature* 1994;370:463–7.
- Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune response with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. *J Virol* 1994;68:4650–5.
- Connick E, Marr DG, Zhang XQ, et al. HIV-specific cellular and humoral immune responses in primary HIV infection. *AIDS Res Hum Retroviruses* 1996;12:1129–40.
- D'Souza MP, Mathieson BJ. Early phases of HIV-1 infection. *AIDS Res Hum Retroviruses* 1996;12:1–9.
- Gallarda JL, Henrard DR, Liu D, et al. Early detection of antibody to human immunodeficiency virus type 1 by using antigen conjugate immunoassay correlates with the presence of immunoglobulin M antibody. *J Clin Microbiol* 1992;30:2379–84.
- Moore JP, Cao Y, Ho DD, Koup RA. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. *J Virol* 1994;68:5142–55.

10. Ariyoshi K, Harwood E, Chiengsong-Popov R, Weber J. Is clearance of HIV-1 viremia at seroconversion mediated by neutralising antibodies? *Lancet* **1993**;340:1257–8.
11. Reimann KA, Tenner-Racz K, Racz P, et al. Immunopathogenic events in the acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. *J Virol* **1994**;68:2362–70.
12. Montefiori DC, Baba TW, Li A, Bilaska M, Ruprecht RM. Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239Δ3 in adult and infant rhesus monkeys. *J Immunol* **1996**;157:5528–35.
13. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunological progression. *AIDS* **1994**;8:1123–8.
14. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. The characterization of non-progressors: long-term HIV-1 infection with stable CD4⁺ T-cell levels. *AIDS* **1993**;7:1159–66.
15. Munoz A, Kirby AJ, He YD, Margolick JB, Visscher BR, Rinaldo CR, Kaslow RA, Phair JP. Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4⁺ lymphocytes. *J Acquir Immune Defic Syndr* **1995**;8:496–505.
16. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. *N Engl J Med* **1995**;332:209–16.
17. Montefiori DC, Pantaleo G, Fink LM, et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. *J Infect Dis* **1996**;173:60–7.
18. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. *N Engl J Med* **1995**;332:201–8.
19. Klein MR, van Baalen CA. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. *J Exp Med* **1995**;181:1356–72.
20. Rinaldo C, Huang XL, Fan Z, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. *J Virol* **1995**;69:5838–42.
21. Harrer T, Harrer E, Kalams SA, et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable non-progressing HIV type 1 infection. *AIDS Res Hum Retroviruses* **1996**;12:585–92.
22. Kirchoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Absence of intact *nef* sequences in a long-term survivor with nonprogressive HIV-1 infection. *N Engl J Med* **1995**;332:228–32.
23. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the *CKR5* structural gene. *Science* **1996**;273:1856–62.
24. Johnson VA, Byington RE. Infectivity assay (virus yield assay). In: Aldovini A, Walker BD, eds. *Techniques in HIV research*. New York: Stockton Press, **1990**:71–6.
25. Montefiori DC, Robinson WE Jr, Schuffman SS, Mitchell WM. Evaluation of antiviral drugs and neutralizing antibodies against human immunodeficiency virus by a rapid and sensitive microtiter infection assay. *J Clin Microbiol* **1988**;26:231–7.
26. Montefiori DC, Reimann KA, Letvin NL, Zhou J, Hu SL. Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. *AIDS Res Hum Retroviruses* **1995**;11:963–70.
27. Dewart R, Highbarger H, Sarmiento M, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. *J Infect Dis* **1994**;170:1172–9.
28. Burton DR, Montefiori DC. The antibody response in HIV-1 infection. *AIDS* **1997**;11(suppl A):S87–98.
29. Wrin T, Crawford L, Sawyer L, Weber P, Sheppard HW, Hanson CV. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. *J Acquir Immune Defic Syndr* **1994**;7:211–9.
30. Delwart EL, Sheppard HW, Walker BD, Goudsmit J, Mullins JI. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. *J Virol* **1994**;68:6672–83.
31. Albert J, Abrahamsson B, Nagy K, et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. *AIDS* **1990**;4:107–12.
32. Tremblay M, Wainberg MA. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. *J Infect Dis* **1990**;162:735–7.
33. Arendrup M, Nielsen C, Stig Hansen JE, Pedersen C, Mathiesen L, Nielsen JO. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. *J Acquir Immune Defic Syndr* **1992**;5:303–7.
34. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8⁺ T cells. *Science* **1995**;270:1811–5.
35. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. *Nature* **1996**;382:829–32.
36. Oberlin E, Amara A, Bachelier F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. *Nature* **1996**;382:833–5.
37. McKenzie SW, Dallalio G, North M, Frame P, Means RT Jr. Serum chemokine levels in patients with non-progressing HIV infection. *AIDS* **1996**;10:F29–33.
38. Hirsch V, Adger-Johnson D, Campbell B, et al. A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. *J Virol* **1997**;71:1608–20.
39. Bou-Habib DC, Roderiquez G, Oravec T, Berman PW, Lusso P, Norcross MA. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. *J Virol* **1994**;68:6006–13.
40. Choe H, Farzan M, Sun Y, et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. *Cell* **1996**;85:1135–48.
41. Oravec T, Marina P, Norcross MA. β-chemokine inhibition of monocytotropic HIV-1 infection. *J Immunol* **1996**;157:1329–32.
42. Connick E, Marr DG, Zhang XQ, et al. HIV-specific cellular and humoral immune responses in primary HIV infection. *AIDS Res Hum Retroviruses* **1996**;12:1129–40.
43. Zhou JT, Montefiori DC. Complement-activating antibodies that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1/CD35). *Virology* **1996**;226:13–21.
44. Montefiori DC, Graham BS, Zhou JY, Zhou JT, Ahearn JM. Binding of human immunodeficiency virus type 1 to the C3b/C4b receptor, CR1 (CD35), and red blood cells in the presence of envelope-specific antibodies and complement. *J Infect Dis* **1994**;170:429–32.
45. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation times. *Science* **1996**;271:1582–6.